Herantis Pharma Oyj (HEL:HRTIS)

Market Cap	54.21M
Revenue (ttm)	n/a
Net Income (ttm)	-5.45M
Shares Out	24.09M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	85,212
Average Volume	183,704
Open	2.270
Previous Close	2.230
Day's Range	2.230 - 2.320
52-Week Range	1.180 - 3.870
Beta	0.22
RSI	55.01
Earnings Date	Nov 21, 2025

About Herantis Pharma Oyj

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. The company was incorporated in 2008 and is based in Espoo, Finland.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 11
• Stock Exchange: Nasdaq Helsinki
• Ticker Symbol: HRTIS